| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 221 | MICROCRYSTALLINE CEWLLULOSE COMPOSITIONS | EP03728896.6 | 2003-05-14 | EP1575487A4 | 2012-12-05 | TUASON, Domingo, C.; AMUNDARAIN, Jose; KRAWCZYK, Gregory, R.; SELINGER, Edward; BLAKEMORE, William, R.; MODLISZEWSKI, James, J.; LEE, Joseph; MESSICK, Frank |
| 222 | INTERLEUKIN-4 (IL-4) FOR USE IN THE TREATMENT OF MYOCARDIAL INFARCTION | PCT/GB2017/050536 | 2017-02-28 | WO2017149291A1 | 2017-09-08 | SUZUKI, Ken |
The present invention provides compositions and pharmaceutical compositions of lnterleukin-4 (IL- 4) for use in the treatment of myocardial infarction (Ml). The invention further provides methods of treatment accordingly as well as kits for use, including a drug eluting implantable medical device comprising IL-4 for use in the treatment of Ml. |
||||||
| 223 | DETERMINATION OF PLATELET-MIRNAS IN ACUTE MYOCARDIAL INFARCTION | PCT/EP2014078766 | 2014-12-19 | WO2015091963A3 | 2015-10-15 | MEDER BENJAMIN; BEIER MARKUS; VOGEL BRITTA; KATUS HUGO |
| The present invention relates to methods, kits and uses for determining platelet-miRNAs in a whole blood sample from a subject affected or suspected to be affected by Acute Myocardial Infarction. | ||||||
| 224 | SUPPRESSION OF HIGH RATE PACING FOR REDUCING MYOCARDIAL ISCHEMIC IRRITABILITY | PCT/US2006015397 | 2006-04-24 | WO2006118846A2 | 2006-11-09 | JACKSON TROY E |
| An implantable cardiac stimulation device capable of delivering automatic rate-adjusting pacing therapies is provided having an adjustable upper rate limit responsive to an indication of myocardial irritability. The implantable device, which may be embodied as a pacemaker, a pacemaker/cardioverter/defibrillator, or the like, responds to the detection of an arrhythmia as an indicator of myocardial irritability by adjusting an upper rate limit. The adjusted upper rate limit is applied as the maximum allowable pacing rate during delivery of any pacing therapies previously defined as "long-term" pacing therapies. | ||||||
| 225 | TREATMENT OF ACUTE MYOCARDIAL INFARCTION WITH A SUBSTANCE RELATED TO THE GROWTH HORMONE AXIS | PCT/SE2000/000844 | 2000-05-03 | WO00067770A1 | 2000-11-16 | |
| Disclosed is the use of a substance related to the growth hormone axis, such as growth hormone (GH), growth hormone secretagogues (GHSs), e.g. growth hormone release peptide (GHRP), and insulin like growth factor I (IGF-I), or of a combination of two or more such substances, for the production of a pharmaceutical preparation for treatment of an acute ischemic event, such as an acute myocardial infarction. Also a method for treatment of an acute ischemic event, such as an acute myocardial infarction, wherein a substance related to the growth hormone axis is administered to a patient, is disclosed. | ||||||
| 226 | USE OF CARDIOTROPHIN IN HEPATIC DISEASES | EP02772422.8 | 2002-09-20 | EP1437365B1 | 2008-12-03 | BUSTOS DE ABAJO, Matilde; PRIETO VALTUEÑA, Jesús; LASARTE SAGASTIBELZA, Juan, José; BAIXERAS LLANO, Elena |
| The invention relates to the use of cardiotrophin in hepatic diseases. The invention describes the increased expression of cardiotrophine (CT-1) during the hepatic regeneration process which coincides with the maximum proliferation of hepatocytes. Said invention also relates to the role of CT-1 as a hepatic regeneration stimulator. Moreover, said invention details the hepatoprotective role of CT-1 in different acute hepatic injury models. All of the above reveals the importance of the use of CT-1 in the production of compositions used in the treatment of hepatopathies. The invention relates to said use of CT-1 in different forms and methods, including the recombinant protein and the use of gene sequences that code for CT-1. | ||||||
| 227 | 15-케토-프로스타글란딘 화합물을 함유한 심근 수축 증강용 약제학적 조성물 | KR1019900018960 | 1990-11-22 | KR1019910009270A | 1991-06-28 | 우에노류지; 오사마히로요시 |
| 내용 없음 | ||||||
| 228 | METHODS FOR TREATING ACUTE MYOCARDIAL INFARCTION BY CALCITONIN GENE RELATED PEPTIDE AND COMPOSITIONS CONTAINING THE SAME | PCT/US2005001224 | 2005-01-13 | WO2005070444A3 | 2006-12-21 | SOUTHARD JEFFREY L; SOUTHARD GEORGE LEE |
| The present invention provides methods of treating and preventing mortality associated with heart failure and renal insufficiency in a Stage B, C, or D heart failure patient, and for improving quality of life by providing improved methods of administering a therapeutically effective amount CGRP. One method comprise administering between about 50 and about 500 ng/min of CGRP for a time between 30 minutes and 8 hours per day for as many days as needed to provide symptomatic relief, prevent exacerbation of symptoms, and/or prevent and/or delay progression of the disease state of heart failure in said patient. The therapies can be administered on an outpatient or inpatient basis. | ||||||
| 229 | COMBINATION OF ANGIOTENSIN II RECEPTOR BLOCKER AND BETA-BLOCKER FOR SECONDARY PREVENTION OF MYOCARDIAL INFARCTION | PCT/EP2003/005198 | 2003-05-16 | WO2003097099A1 | 2003-11-27 | CALIFF, Robert, M.; MACNAB, Malcolm; McMURRAY, John, J., V.; PFEFFER, Marc, A. |
The invention relates to a method of treating cardiovascular disease in patients following myocardial infarction comprising administering an effective amount of an ARB, especially valsartan, in combination within an effective amount of a beta-blocker to such patients. |
||||||
| 230 | USE OF THE INSULIN-LIKE-GROWTH FACTOR I SPLICE VARIANT MGF FOR THE PREVENTION OF MYOCARDIAL DAMAGE | PCT/GB2003/000537 | 2003-02-06 | WO2003066082A1 | 2003-08-14 | GOLDSPINK, Geoffrey; GOLDSPINK, Paul |
The invention relates to the use of a Mechano Growth Factor (MGF) polypeptide or a polynucleotide encoding an MGF polypeptide in the manufacture of a medicament for the prevention or limitation of myocardial damage in response to ischemia or mechanical overload of the heart by preventing or limiting apoptosis in the myocardium. |
||||||
| 231 | MICRORNA-294 AND LN28A AS A DRIVER OF CARDIAC TISSUE PROLIFERATION IN RESPONSE TO PATHOLOGICAL INJURY | PCT/US2017/027876 | 2017-04-17 | WO2017181166A1 | 2017-10-19 | KHAN, Mohsin; KISHORE, Raj |
The invention provides one or more of miR-290 family and Lin28a modified cardiac progenitor cell based therapies for the treatment of myocardial infarction. Exosomes derived from one or more of miR-290 family and Lin28a modified cardiac progenitor cells can also be used in cardiac therapy. |
||||||
| 232 | ENDOMYOCARDIAL MONOPHASIC ACTION POTENTIAL FOR EARLY DETECTION OF MYOCARDIUM PATHOLOGY | PCT/US2000/009104 | 2000-04-04 | WO00059375A1 | 2000-10-12 | |
| A "lantern catheter" devised according to the invention is used for transpercutaneous catheterization followed by three-dimensionally mapping the endomyocardial monophasic action potential (MAP). Preferably at least 64 points of MAP are recorded simultaneously and the data analyzed by a conventional electrophysiological (EP) analysis system. The invention is comprised of three components: 1) the use of three-dimensional mapping of the endomyocardium (MAP) to determine the myocardium injury/electrical-pathophysiology of cardiac myocytes induced by cardiac rejection, ischemia, inflammation and the like; 2) a technology and design of the lantern catheter for endomyocardial MAP mapping; and 3) a diagnostic criteria for the cardiac myocyte injury. During allograft rejection, conduction impairment occurs only within the atrial myocardium. | ||||||
| 233 | METHODS FOR TREATING ACUTE MYOCARDIAL INFARCTION BY ADMINISTERING CALCITONIN GENE RELATED PEPTIDE AND COMPOSITIONS CONTAINING THE SAME | PCT/US2005001230 | 2005-01-13 | WO2005070445A2 | 2005-08-04 | SOUTHARD JEFFREY L; SOUTHARD GEORGE LEE |
| This invention relates to methods of treating acute myocardial infarction by administering calcitonin gene related peptide (CGRP). This invention also relates to preventing an acute myocardial infarction by administering calcitonin gene related peptide (CGRP). This invention further relates to compositions of CGRP for use in such methods. This invention also relates to the use of calcitonin gene related peptide in the manufacture of medicament for treating or preventing an acute myocardial infarction in a subject or for treating a subject suspected of having an acute myocardial infarction. | ||||||
| 234 | RISK FACTORS AND PREDICTION OF MYOCARDIAL INFARCTION | EP10781559.9 | 2010-11-15 | EP2499489A1 | 2012-09-19 | ADOURIAN, Aram, S.; GUO, Yu; LI, Xiaohong; MUNTENDAM, Pieter |
| Biomarkers and methods are disclosed for diagnosing the risk of a myocardial infarction in an individual by measuring the levels of a set of biomarkers in a sample from an individual. A risk score is calculated for the individual by weighting the measured levels of the biomarkers. The risk score then is used to identify whether the individual is likely to experience a myocardial infarction. In addition, kits are disclosed that include a set of reagents for specifically measuring biomarker levels in a sample from an individual. | ||||||
| 235 | Risk Factors and Prediction of Myocardial Infaraction | EP12195913.4 | 2010-11-15 | EP2568294B1 | 2015-01-07 | Adourian, Aram S.; Guo, Yu; Li, Xiaohong; Muntendam, Pieter |
| 236 | RISK FACTORS AND PREDICTION OF MYOCARDIAL INFARCTION | EP10781559.9 | 2010-11-15 | EP2499489B1 | 2015-01-07 | ADOURIAN, Aram, S.; GUO, Yu; LI, Xiaohong; MUNTENDAM, Pieter |
| 237 | USE OF CARDIOTROPHIN- 1 FOR THE TREATMENT OF METABOLIC DISEASES | EP10710061.2 | 2010-02-10 | EP2397152B1 | 2014-05-28 | PRIETO VALTUEÑA, Jesús María; BUSTOS DE ABAJO, Matilde; MORENO ALIAGA, María Jesús |
| 238 | Utilisation de la médifoxamine pour l'amélioration des performances psychomotrices | EP86401389.1 | 1986-06-24 | EP0212998A3 | 1989-09-27 | Rolland, Anne |
L'invention se rapporte au domaine de la chimie pharmaceutique et plus particulièrement au domaine de la thérapeutique. Elle concerne des compositions pharmaceutiques améliorant les performances psychomotrices qui renferment, à titre de principe actif, une quantité neurologiquement active de 2,2-bis phénoxy NN-dimethyléthylamine en association ou en mélange avec un excipient ou un véhicule pharmaceutique. Les compositions de l'invention trouvent un emploi thérapeutique dans le traitement de la fatigue intellectuelle. |
||||||
| 239 | SPIROCYCLIC HETEROCYCLE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | EP14870755.7 | 2014-12-17 | EP3083641A4 | 2017-06-14 | GRAHAM, Thomas, H.; LIU, Wensheng; YU, Tao; ZHANG, Yonglian; WADDELL, Sherman, T.; WAI, John, S.; COLEMAN, Paul, J.; SANDERS, John, M.; EMBREY, Mark, W.; WALJI, Abbas, M.; FERGUSON, Ronald Dale, II; DI MARCO, Christina Ng; STEELE, Thomas, G.; HU, Lihong; PENG, Xuanjia |
| 240 | USE OF CARDIOTROPHIN TO MODULATE STEM CELL PROLIFERATION | EP04737879.9 | 2004-06-25 | EP1639003B1 | 2010-04-07 | MEGENEY, Lynn |
| Methods of promoting stem cell proliferation comprising contacting the cells with cardiotrophin-1 (CT-1) are provided. The methods may further comprise contacting the stem cells with one or more stem cell modulators that promote differentiation of the stem cells. Methods of inhibiting stem cell proliferation comprising contacting the cells with one or more CT-1 inhibitor are also provided. The methods can be used to promote or inhibit stem cell proliferation in vitro and in vivo. Therapeutic applications of the methods in the replacement of damaged or defective tissue or in the inhibition of inappropriate cell proliferation are also provided. | ||||||
QQ群二维码
意见反馈
意见反馈